Form 4: Cogent Biosciences CFO Sells 77,000 Shares

John L. Green, Chief Financial Officer of Cogent Biosciences, Inc., sold 77,000 shares of common stock at a weighted average price of $38.68 per share.

Summary

• John L. Green, Chief Financial Officer of Cogent Biosciences, Inc. (COGT), reported a sale of common stock.
• The transaction involved the disposition of 77,000 shares of common stock.
• The shares were sold on December 26, 2025, at a weighted average price of $38.68 per share.
• The sales occurred in multiple transactions at prices ranging from $38.51 to $38.94 per share.
• Following this transaction, John L. Green beneficially owns 131,834 shares of common stock directly.
• The reported transaction was made pursuant to a Rule 10b5-1(c) plan.
• The remaining beneficial ownership includes previously reported restricted stock units subject to certain vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine insider transaction filed under a Rule 10b5-1 plan, which typically indicates a pre-scheduled sale for personal financial planning rather than a reaction to company-specific news. The sale amount is significant but not extraordinary relative to the remaining holdings.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to immediate company news or market conditions.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived as a lack of confidence by some investors, though this is mitigated by the 10b5-1 plan.

Future Outlook

N/A. This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

N/A. This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitor analysis.

Stakeholder Impact

• Shareholders: The sale by a Chief Financial Officer, even under a 10b5-1 plan, may lead to minor scrutiny, but the pre-planned nature mitigates concerns about immediate negative implications for the company's prospects.

Key Dates

Keywords

Cogent Biosciences, COGT, Form 4, Insider Trading, Stock Sale, John L. Green, Chief Financial Officer, 10b5-1 Plan, Equity Transaction